Yabing Guo

2.9k total citations · 1 hit paper
15 papers, 270 citations indexed

About

Yabing Guo is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Yabing Guo has authored 15 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 6 papers in Epidemiology and 5 papers in Oncology. Recurrent topics in Yabing Guo's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Hepatitis B Virus Studies (6 papers) and Liver Disease Diagnosis and Treatment (3 papers). Yabing Guo is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Hepatitis B Virus Studies (6 papers) and Liver Disease Diagnosis and Treatment (3 papers). Yabing Guo collaborates with scholars based in China, Hong Kong and United States. Yabing Guo's co-authors include Yuxian Bai, Zhiqiang Meng, Donatella Marino, Richard S. Finn, Frédéric Boisserie, Arndt Vogel, Shukui Qin, Taroh Satoh, Andrew X. Zhu and Eric Assénat and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Experimental Cell Research.

In The Last Decade

Yabing Guo

14 papers receiving 266 citations

Hit Papers

Tislelizumab vs Sorafenib as First-Line Treatment for Unr... 2023 2026 2024 2025 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
    2023 136 citations Shukui Qin, Masatoshi Kudo et al. JAMA Oncology profile →

Peers

Yabing Guo
Vennis Lourdusamy United States
Cheng‐Qian Zhong China
M.L. González-Diéguez Spain
Juan Vaz Sweden
Wen‐Bin Ding China
Jiali Chen China
Zili Hu China
Matthew L. Holzner United States
Jiashuo Chao China
Sophie Dominguez France
Vennis Lourdusamy United States
Yabing Guo
Citations per year, relative to Yabing Guo Yabing Guo (= 1×) peers Vennis Lourdusamy

Countries citing papers authored by Yabing Guo

Since Specialization
Citations

This map shows the geographic impact of Yabing Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yabing Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yabing Guo more than expected).

Fields of papers citing papers by Yabing Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yabing Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yabing Guo. The network helps show where Yabing Guo may publish in the future.

Co-authorship network of co-authors of Yabing Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Yabing Guo. A scholar is included among the top collaborators of Yabing Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yabing Guo. Yabing Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Zheng, Yuanyuan, Yiran Wang, Fei Zhou, et al.. (2025). Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors. Therapeutic Advances in Medical Oncology. 17. 22792205–22792205.
2.
Chan, Stephen L., Zhenggang Ren, Yuxian Bai, et al.. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.. Journal of Clinical Oncology. 42(16_suppl). 4110–4110. 16 indexed citations
3.
Chen, Jinzhang, Mengya Zang, Chuanjiang Li, et al.. (2023). Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).. Journal of Clinical Oncology. 41(16_suppl). e16128–e16128. 3 indexed citations
4.
5.
Qin, Shukui, Masatoshi Kudo, Tim Meyer, et al.. (2023). Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. JAMA Oncology. 9(12). 1651–1651. 136 indexed citations breakdown →
6.
Guo, Yabing, Tian Geng, Xin Chen, et al.. (2023). GL-V9 ameliorates liver fibrosis by inhibiting TGF-β/smad pathway. Experimental Cell Research. 425(1). 113521–113521. 9 indexed citations
7.
Ren, Zhenggang, Jianming Xu, Yuxian Bai, et al.. (2023). Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 41(4_suppl). 530–530. 1 indexed citations
8.
Ren, Zhenggang, Jianming Xu, Yuxian Bai, et al.. (2023). ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 41(4_suppl). 570–570. 7 indexed citations
9.
10.
Zang, Mengya, Qi Li, Guosheng Yuan, et al.. (2022). Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil in intermediate and advanced hepatocellular carcinoma: A retrospective study.. Journal of Clinical Oncology. 40(16_suppl). e16166–e16166. 3 indexed citations
11.
Ma, Rong, Heng Zhang, Yabing Guo, et al.. (2021). miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma. Frontiers in Oncology. 11. 671144–671144. 12 indexed citations
12.
Wang, Haiyu, Fuyuan Zhou, Yabing Guo, et al.. (2020). Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. Journal of Hepatology. 74(3). 584–592. 48 indexed citations
13.
Yuan, Guosheng, et al.. (2015). Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.. PubMed. 8(8). 13524–31. 5 indexed citations
14.
Li, Linfang, et al.. (2008). [Factors influencing the success rate and stability of transient elastography for liver fibrosis evaluation].. PubMed. 28(4). 595–7. 4 indexed citations
15.
Li, Lijie, et al.. (2007). Protective effects of medical ozone combined with traditional Chinese medicine against chemically-induced hepatic injury in dogs. World Journal of Gastroenterology. 13(45). 5989–5989. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vennis Lourdusamy Breakdown of academic impact, for papers by Cheng‐Qian Zhong Breakdown of academic impact, for papers by M.L. González-Diéguez Breakdown of academic impact, for papers by Juan Vaz Breakdown of academic impact, for papers by Wen‐Bin Ding Breakdown of academic impact, for papers by Jiali Chen Breakdown of academic impact, for papers by Zili Hu Breakdown of academic impact, for papers by Matthew L. Holzner Breakdown of academic impact, for papers by Jiashuo Chao Breakdown of academic impact, for papers by Sophie Dominguez
Rankless by CCL
2026